Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01474421 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 71
- Enrollment target
NCT01474421 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 71 participants.
The verdict
NCT01474421, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 71 participants
- Enrollment target
Study Summary
This study will assess the safety, tolerability and efficacy of AQW051 in treating moderate to severe L-dopa induced dyskinesias (movement disorders) in patients with Parkinson's disease.
Interventions
- DRUG Placebo
- DRUG AQW051
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2011-09-15 |
| Est. Completion | 2013-02-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01474421
The ClinicalTrials.gov registry entry for NCT01474421 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01474421 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01474421 about?
NCT01474421 is a clinical study titled "Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease". This study will assess the safety, tolerability and efficacy of AQW051 in treating moderate to severe L-dopa induced dyskinesias (movement disorders) in patients with Parkinson's disease.
What is the current status of trial NCT01474421?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 71 participants. The study started on 2011-09-15. Estimated completion is 2013-02-21.
What interventions are being tested in trial NCT01474421?
The interventions under investigation include: Placebo (DRUG), AQW051 (DRUG).
Who is sponsoring clinical trial NCT01474421?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.